Phase 1 - Baseline
Stable signal behavior.
The physiological time series remains within expected variability. No transition pattern is interpreted.
Biomedical signals as a dynamic system.
In biomedical signal research, the functional question comes first: is the condition of the observed physiological signal changing in a meaningful way before the visible event? The application remains experimental, non-clinical and non-diagnostic.
At the technical layer, the analysis can examine quantitative constructs such as stability, pressure, loss of coherence, recovery capacity and transition conditions in the time series, without converting these dynamics into diagnosis, clinical labels or therapeutic conclusions.
Biomedical application: from baseline to guarded system-state interpretation.
In this domain, APS Logic measures whether the state of the signal is changing before the visible event, while preserving a guarded interpretation of any pre-transition pattern.
Phase 2 - Signal Drift
Subtle instability appears.
The signal begins to drift from its ordinary pattern. The system starts revealing a loss of stability before the event dominates.
Phase 3 - Pre-transition Window
A possible anticipatory window opens.
APS Logic measures whether the signal is entering a condition compatible with a subsequent measurable transition.
Phase 4 - Guarded Interpretation
The result is interpreted with caution.
The output describes transition dynamics: the signal is already moving before the event receives its name.
Experimental biological evidence: Atrial Fibrillation + HILO / Aktiia.
APS-BIO-LAB applies the same APS Logic analytical principle to biomedical time series: the event label is an endpoint, while the research object is the changing trajectory of system stability and resilience before it.
Atrial Fibrillation Signal Case
The arrhythmia becomes visible after the signal has already started losing stability.
In the current experimental configuration, APS-BIO-LAB identifies a narrow, high-specificity dynamic phenotype within selected pre-event trajectories, while showing limited sensitivity. This result is experimental and does not establish clinical atrial-fibrillation prediction.
The central point is not the clinical label. It is the measurable change in signal state and resilience that may precede the fully visible event.
High-specificity
experimental phenotype
The value of APS Logic in biomedical signals is the common quantitative reading of changing stability and resilience before the event becomes the only visible explanation.
In this view, atrial fibrillation is not only an event to be detected. It is the visible outcome of a transition that may have a readable trajectory.
HILO / Aktiia · Historical Blind Replay
Real blood-pressure time series extend the biological evidence beyond the atrial-fibrillation case.
APS-BIO-LAB has also been evaluated through a historical blind replay on 1,131 real blood-pressure measurements. This second biological evidence path examines whether the same APS Logic framework remains informative when applied to a different physiological time series and a different transition context.
The HILO / Aktiia replay therefore extends the experimental biological evidence beyond the original atrial-fibrillation study and contributes to the controlled investigation of cross-domain transferability within physiological signals.
Experimental, non-clinical and non-diagnostic evidence. It does not establish clinical prediction, diagnosis or medical-device validation.
Respiratory medicine perspective.
A specialist pneumology perspective has already framed APS Logic as a shift from symptoms and late events toward loss of resilience, systemic pressure and Silent Convergence Window.
This defines a possible research direction for respiratory-instability dynamics, to be subjected to dedicated experimental validation before any clinical interpretation.
From event-centered reading to quantitative dynamic-resilience measurement.
The biomedical research value of APS Logic is not another label. It is a different analytical observation point: measuring how stability and resilience are changing while the transition is still forming.
Event-centered reading
Sees: the named event, the visible episode, the threshold already crossed.
Question: what is happening now?
Limit: the system has already entered the visible phase of instability.
The label arrives after the transition has matured.
APS dynamic-state reading
Sees: drift, loss of resilience, convergence, recovery capacity and pre-transition instability.
Question: how is the system state changing, and when does resilience begin to weaken?
Strength: the signal is read while the transition is still forming.
The event label is late. The change in stability and resilience may begin earlier.
Biomedical Logic
APS Logic moves the biomedical analytical question upstream.
In biomedical time-series research, the visible event is an endpoint. The analytical object is whether the observed system is measurably changing stability and resilience before that endpoint becomes dominant.
This is the conceptual bridge between biomedical signals and the wider APS Logic framework: the domain changes, while the analytical question remains how the state of the observed system is changing.